iRadimed (NASDAQ:IRMD) Cut to Hold at Wall Street Zen

Wall Street Zen cut shares of iRadimed (NASDAQ:IRMD) from a buy rating to a hold rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings downgraded iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $120.00.

iRadimed Stock Performance

NASDAQ:IRMD opened at $90.27 on Friday. The stock has a 50-day simple moving average of $94.51 and a 200 day simple moving average of $95.26. iRadimed has a one year low of $67.84 and a one year high of $107.90. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of 50.43 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. The business had revenue of $20.47 million during the quarter, compared to the consensus estimate of $20.35 million. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, equities research analysts forecast that iRadimed will post 1.52 EPS for the current fiscal year.

iRadimed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 28th. Stockholders of record on Friday, August 14th will be issued a $0.20 dividend. The ex-dividend date is Friday, August 14th. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. iRadimed’s dividend payout ratio is 44.69%.

Insider Buying and Selling at iRadimed

In other news, CEO Roger E. Susi sold 5,000 shares of the firm’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $87.51, for a total transaction of $437,550.00. Following the completion of the transaction, the chief executive officer owned 2,175,000 shares in the company, valued at approximately $190,334,250. This trade represents a 0.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 10,000 shares of company stock worth $883,750. Company insiders own 34.60% of the company’s stock.

Institutional Investors Weigh In On iRadimed

Several large investors have recently modified their holdings of the stock. CWM LLC boosted its stake in iRadimed by 19.5% in the 4th quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock worth $64,000 after purchasing an additional 107 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in iRadimed by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock valued at $252,000 after purchasing an additional 234 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of iRadimed by 4.8% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,824 shares of the medical equipment provider’s stock valued at $567,000 after buying an additional 267 shares in the last quarter. Quantinno Capital Management LP grew its position in iRadimed by 12.5% in the first quarter. Quantinno Capital Management LP now owns 3,482 shares of the medical equipment provider’s stock worth $335,000 after acquiring an additional 387 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its holdings in iRadimed by 827.1% in the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 397 shares in the last quarter. 92.34% of the stock is owned by institutional investors.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.